Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials

Main Article Content

D Thaçi
A Blauvelt
K Reich
RB Warren
V Piguet
F Brock
F Fierens
V Ciaravino
M Lebwohl

Keywords

Plaque Psoriasis, Biologic, Certolizumab Pegol, Quality of Life, Durability

Abstract

Abstract not available.

References

1. Gordon K. Br J Dermatol 2020; doi.org/10.1111/bjd.19393

2. Blauvelt A. Br J Dermatol 2020; doi.org/10.1111/bjd. 19314

3. Bhosle MJ. Health Qual Life Outcomes 2006;4:35

4. Optum. SF-36v2 Health Survey. Available at www.optum.com/solutions/life-sciences/answer-research/patient-insights/sf-health-surveys/sf-36v2-health-survey [Accessed 25th
March 2020].